Fiche centre
Hospital Clinic de Barcelona
Barcelona — Spain
Essais liés29clinical trials
VilleBarcelonalocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07028879
Essais cliniques associés
29| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tricuspid Transcatheter Edge-to-Edge Repair (TEER) | Maladie coronarienne | À vérifier | NCT07586995 | TREAT TR — A Post-Market Assessment of the Safety and Performance of the TriClip™ System | RECRUITING |
| Pleneva TM BGC20-0134 | SEP | Phase 2 | NCT01037907 | A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | TERMINATED |
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Implant of investigational device system | Insuffisance cardiaque | Non applicable | NCT01385176 | Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) | ACTIVE_NOT_RECRUITING |
| Angiographic Guided PCI | Maladie coronarienne | Non applicable | NCT07422688 | OCTAVE — Optical Coherence Tomography in Acute Vessel Evaluation | ENROLLING_BY_INVITATION |
| Adagrasib | Cancer | Phase 2/3 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | RECRUITING |
| Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold | Maladie coronarienne | Non applicable | NCT07091682 | BIOMAG-LL — Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | ACTIVE_NOT_RECRUITING |
| Edoxaban | Accident vasculaire cérébral | Phase 4 | NCT03950076 | EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) | COMPLETED |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | RECRUITING |
| Elective redo transcatheter aortic valve implantation (redo-TAVI) | Insuffisance cardiaque | À vérifier | NCT05601453 | The ReTAVI Prospective Observational Registry | RECRUITING |
| Active Colchicine | Maladie coronarienne | Phase 3 | NCT03310125 | Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) | COMPLETED |
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| Arm A: Gedatolisib + Palbociclib + Fulvestrant | Cancer | Phase 3 | NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING |
| Elacestrant | Cancer | Phase 1/2 | NCT05386108 | ELECTRA — Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | RECRUITING |
| RO7268489 | SEP | Phase 2 | NCT07282574 | Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) | RECRUITING |
| Fatigue management program | SEP | Non applicable | NCT07028879 | HCB_MS — Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis | COMPLETED |
| Zanidatamab | Cancer | Phase 3 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | RECRUITING |
| RO7046015 | Parkinson | Phase 2 | NCT03100149 | PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| Nerandomilast | Myopathies | Phase 3 | NCT07789015 | VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | NOT_YET_RECRUITING |
| BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | Lupus | À vérifier | NCT07175285 | BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | RECRUITING |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06641466 | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | RECRUITING |
| CC-97540 | Myasthénie | Phase 1 | NCT06220201 | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | ACTIVE_NOT_RECRUITING |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |